Ipamorelin Reviews, Clinical Trials, And Safety Ipamorelin Reviews, Clinical Trials, And Safety Ipamorelin Reviews, Clinical Trials, And Safety --- Compound Overview Ipamorelin is a synthetic hexapeptide that stimulates the release of growth hormone (GH) through selective agonism of the ghrelin receptor (GHS-R1a). Unlike older GH secretagogues such as GHRP-2 and GHRP-6, ipamorelin has a higher selectivity profile and a lower propensity to trigger prolactin or cortisol release. Its primary therapeutic interest lies in promoting anabolic processes, enhancing tissue repair, and potentially extending healthy lifespan. Class of Compound Ipamorelin belongs to the class of growth hormone secretagogues (GHS). These peptides mimic ghrelin’s action but are engineered for improved stability, potency, and reduced side-effects. They are typically administered via subcutaneous injection due to their peptide nature. Mechanism of Action When ipamorelin binds to GHS-R1a receptors on pituitary somatotrophs, it activates the Gq protein signaling cascade, leading to phospholipase C activation and intracellular calcium release. The rise in calcium promotes GH exocytosis. Because ipamorelin is a partial agonist at GHS-R1a, it produces robust GH secretion without significantly influencing prolactin or cortisol pathways. Notable Studies Longitudinal GH Secretion Study (2013): Participants receiving 100 µg of ipamorelin twice daily for six weeks showed a 45 % increase in overnight GH output with minimal changes in insulin-like growth factor-1 (IGF-1) levels. Muscle Recovery Trial (2015): Athletes treated with ipamorelin during post-exercise periods reported faster muscle protein synthesis rates and reduced soreness compared to placebo.